Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nebulized Albuterol Will Not Get NCD Due To Lack Of Data On Patient Subgroups, But Xopenex Loses On Payment Side

This article was originally published in The Pink Sheet Daily

Executive Summary

Medicare Part B coverage policy for nebulized beta adrenergic agonist therapy for lung disease will continue to be the purview of local Medicare claims contractors.

You may also be interested in...



A Closer Look: Decision For No Medicare NCD On ESAs In Renal Disease Would Be The Exception

Many industry watchers were surprised when the Centers for Medicare and Medicaid Services conducted an extensive evidence analysis of ESAs, only to propose on March 16 no policy change. Indeed, the outcome, if made final, would be quite unusual, a look at numerous coverage analyses shows.

A Closer Look: Decision For No Medicare NCD On ESAs In Renal Disease Would Be The Exception

Many industry watchers were surprised when the Centers for Medicare and Medicaid Services conducted an extensive evidence analysis of ESAs, only to propose on March 16 no policy change. Indeed, the outcome, if made final, would be quite unusual, a look at numerous coverage analyses shows.

Sepracor Will Ramp Up Sales Force To Launch NycoMed Drugs

Company will add 200 reps this year to promote Omnaris and Alvesco, as well as existing products like Lunesta.

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel